![Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment- naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial - The Lancet Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment- naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001012426/2003805168/gr1.gif)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment- naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial - The Lancet
Mucosal immunization with VLP requires adjuvant activity in aged mice... | Download Scientific Diagram
![Frontiers | Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8+ T Cell Transcriptional Programs Frontiers | Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8+ T Cell Transcriptional Programs](https://www.frontiersin.org/files/Articles/691997/fimmu-12-691997-HTML/image_m/fimmu-12-691997-g002.jpg)
Frontiers | Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8+ T Cell Transcriptional Programs
![Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01842-3/MediaObjects/12325_2021_1842_Fig5_HTML.png)
Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink
Reduced Number of Transitional and Naive B Cells in Addition to Decreased BAFF Levels in Response to the T Cell Independent Immunogen Pneumovax®23 | PLOS ONE
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir
![Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01842-3/MediaObjects/12325_2021_1842_Fig2a_HTML.png)
Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan | SpringerLink
![An atypical lipoteichoic acid from <i>Clostridium perfringens</i> elicits a broadly cross-reactive and protective immune response. - Abstract - Europe PMC An atypical lipoteichoic acid from <i>Clostridium perfringens</i> elicits a broadly cross-reactive and protective immune response. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7363129/bin/SB-JBCJ200080F008.jpg)